NN2211, a Novo Nordisk GLP-1 derivate, suppresses appetite in wild type but not in GLP-1R-/- mice

被引：0
|
作者：
Bjenning, CA [1 ]
Romer, J [1 ]
Knudsen, LB [1 ]
机构：
[1] Novo Nordisk AS, DK-2820 Gentofte, Denmark
来源：
OBESITY RESEARCH | 2001年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：119S / 119S
页数：1
相关论文
共 50 条
  • [1] An immunoassay for the GLP-1 derivative NN2211
    Wilken, M
    Larsen, FS
    Juul, AG
    Jensen, LB
    Ribel, U
    DIABETOLOGIA, 2000, 43 : A148 - A148
  • [2] Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
    Agerso, H
    Vicini, P
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 19 (2-3) : 141 - 150
  • [3] The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of Type 2 diabetes
    Matthews, D
    Madsbad, S
    Schmitz, O
    Langendorf, KW
    Jakobsen, G
    DIABETES, 2002, 51 : A84 - A84
  • [4] A long-acting GLP-1 derivative, NN2211: its use in the treatment of Type 2 diabetes
    Matthews, DR
    Madsbad, S
    Schmitz, O
    Langendorf, KW
    Jakobsen, G
    DIABETOLOGIA, 2002, 45 : A217 - A218
  • [5] Glucose lowering effect of the protracted GLP-1 derivative, NN2211, in the betacell reduced minipig
    Ribel, U
    Hvidt, M
    Larsen, MO
    Rolin, B
    Wilken, M
    Knudsen, LB
    DIABETOLOGIA, 2000, 43 : A145 - A145
  • [6] Effect of the long-acting GLP-1 derivative NN2211 in 60% pancreatectomized rats
    Romer, J
    Pedersen, KE
    Jorgensen, B
    Rothe, P
    Bentsen, E
    Damgaard, N
    Knudsen, LB
    Wassermann, K
    Ribel, U
    DIABETES, 2001, 50 : A312 - A312
  • [7] GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development
    Knudsen, LB
    Agerso, H
    Bjenning, C
    Bregenholt, S
    Carr, RD
    Godtfredsen, C
    Holst, JJ
    Huusfeldt, PO
    Larsen, MO
    Larsen, PJ
    Nielsen, PF
    Ribel, U
    Rolin, B
    Romer, J
    Sturis, J
    Wilken, M
    Kristensen, P
    DRUGS OF THE FUTURE, 2001, 26 (07) : 677 - 685
  • [8] Effect of the long-acting GLP-1 derivative NN2211 in 60% pancreatectomized rats
    Romer, J
    Bentsen, E
    Damgaard, J
    Jorgensen, B
    Pedersen, KE
    Rothe, P
    Knudsen, LB
    Wassermann, K
    Ribel, U
    DIABETOLOGIA, 2001, 44 : A197 - A197
  • [9] Effects of NN2211, a long acting derivative of GLP-1, on β-cell proliferation and β-cell mass in db/db mice
    Gotfredsen, CF
    Larsen, MO
    Knudsen, LB
    DIABETES, 2001, 50 : A31 - A31
  • [10] Pharmacokinetic profile of the long-acting GLP-1 derivative NN2211 in healthy male subjects
    Jakobsen, G
    Agerso, H
    Elbroend, B
    Jensen, LB
    DIABETES, 2001, 50 : A118 - A118
12345